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Abstract
Background: The management of acute respiratory infections (ARIs), urinary tract infections (UTIs), 
and skin and soft tissue infections (SSTIs) should be guided by high quality evidence.
Aim: To compare the quantity and quality of randomised placebo- controlled trials of antibiotics for 
ARIs, UTIs, and SSTIs.
Design & setting: A scoping review of the literature was performed using comprehensive search 
strategies.
Method: PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched 
for published studies from inception until 17 April 2019. Randomised controlled trials (RCTs) that 
compared participants in primary care or in the community who had uncomplicated acute ARI, UTI, 
or studies, and were randomised to antibiotic or placebo (or no active treatment), were eligible for 
inclusion. Two groups of researchers independently screened articles for inclusion, extracted data, 
and assessed the quality of included studies.
Results: A total of 108 eligible studies were identified: 80 on ARI, eight on UTI, and 20 on SSTI. The 
quality of studies varied with unclear risk of bias (RoB) prevalent in many domains. There was a gradual 
improvement in the quality of trials investigating ARIs over time, which could not be assessed in SSTI 
and UTI studies.
Conclusion: This review highlights a sparsity of trials assessing the effectiveness of antibiotics in 
people with UTIs and SSTIs, compared to trials targeting ARIs. This gap in the evidence needs to be 
addressed by conducting further high quality trials on the effects of antibiotics in patients with UTI 
and SSTI.
How this fits in
There is a sparsity of high quality evidence on the effectiveness of antibiotics for UTIs and SSTIs, which 
makes it difficult to produce evidence- based guidelines and patient decision aids for these conditions. 
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This scoping review highlights an important gap in the evidence that needs to be addressed by 
conducting further high quality trials in patients with UTI and SSTI.
Introduction
Widespread antibiotic resistance now threatens a post- antibiotic era.1,2 Reducing antibiotic use is 
widely recognised as a key component to tackling the global antibiotic resistance crisis. Primary care 
is an important focus for this strategy as this is where most antibiotics are prescribed and where 
the benefits from use of antibiotics are often limited.3,4 To assist clinicians in prescribing antibiotics 
appropriately, knowledge about the benefits and harms of their use in various clinical situations is 
needed.
ARIs, SSTIs, and uncomplicated UTIs are the three most common infections seen in primary care, 
with ARIs accounting for 41%–46%, SSTIs accounting for 16%–18%, and UTIs accounting for 9%–23% 
of antibiotics prescribed outside hospitals.5,6 However, an apparent lack of published scientific studies 
on the effectiveness of antibiotics for treating SSTIs and UTIs compared with ARIs was identified. A 
lack of high quality evidence on the effectiveness of antibiotics for SSTIs and UTIs makes it difficult 
to produce evidence- based guidelines and patient decision aids for these conditions. There are also 
implications for a primary research agenda. Accordingly, the authors decided to explore this impression 
by conducting a scoping review of the literature on studies of the effectiveness of antibiotics versus 
placebo (or no treatment) for these infections, and compare the quantity and quality of the RCTs 
addressing this question for these groups of infections.
Method
Eligibility criteria
RCTs were included that compared antibiotic- exposed participants (alone or with any other 
concomitant treatment if that was also available to the placebo group) to placebo (or no treatment) 
controls among patients managed in primary care or in the community, who had uncomplicated acute 
infections of either the respiratory tract, urinary tract, or skin and soft tissue. Studies were excluded 
that: 1) did not have a placebo or no- treatment control; 2) focused on chronic or complicated acute 
infections (for example, persistent cough following acute bronchiolitis, chronic obstructive pulmonary 
disease [COPD], and/or infected diabetic foot ulcers); 3) had recruited hospitalised participants; and 
4) had recruited emergency department patients (except for studies conducted in countries or parts 
of countries where they do not have family or general practices like some states in the US).
Information sources and search strategy
PubMed and CENTRAL were searched from inception until 17 April 2019. Searches for all three 
conditions were done on the same day using the same methods, other than a change of condition- 
specific search terms (see Supplementary Appendix S1 for full search strategy). After identifying the 
included studies, a forward and backward citation analysis was performed using the Scopus database. 
To facilitate the screening process, RobotSearch engine was used to exclude all obvious non- RCTs. 
RobotSearch engine is a validated search engine with high sensitivity and specificity.7
Study selection
Two groups of researchers independently screened the pool of potentially eligible studies using 
Endnote X9 software or the Rayyan website.8 A third reviewer resolved any disagreement.
Data extraction and RoB assessment
A data extraction form was drafted by the research team and the topic areas were divided up between 
the authors (respiratory, urinary, and skin and soft tissue). Each group of authors trialled the form on 
a handful of their different study types and suggested changes. The finalised form was then applied 
by each team across all study types (See Supplementary Box S1 for data extraction form). Two groups 
of authors used a data extraction form to independently extract data on the studied condition (and 
diagnosis), country, sample size, and RoB using items from the Cochrane Risk of Bias tool for RCTs.9
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Synthesis of results
The data were synthesised descriptively, presenting counts, summary tables, and figures that describe 
the number, type, and quality of studies identified.
Results
Figure 1 shows the flow of articles throughout the study. A total of 108 studies were included in the 
final descriptive synthesis. Most studies addressed ARI (n = 80), followed by SSTI (n = 20), and then 
UTI (n = 8) (see Supplementary Box S2 for a complete list of included RCTs).
Quantity of RCTs over time for each of the conditions
The earliest published eligible trial identified was published in 1956, and there was a gradual increase 
in the number of trials published each decade, with a peak for the decade 1991–2000, which saw 30 
RCTs published (28% of total) (Figure 2). The number of RCTs about antibiotic effectiveness for SSTIs 
increased during the period of 2001 to the date of the search (17 April 2019). However, for UTI, there 
were no new RCTs from 2011 until 2019.
Study characteristics
Within each condition, the RCTs investigated a range of diagnoses. The most common are highlighted 
below (refer to Supplementary Table S1 for the characteristics of each RCT). All but 10 RCTs were 
conducted in one of the Organisation for Economic Cooperation and Development countries 
(OECD). Of the ARI RCTs, 19 investigated sinusitis, 17 sore throat, 14 otitis media, 13 non- specific 
ARI, 12 bronchitis, two non- severe pneumonia, two laryngitis, and one rhinitis. Of the SSTI RCTs, 
six investigated skin abscess, four impetigo, three atopic dermatitis, three non- specific SSTI, two 
Figure 1. Study flow chart 
4
Figure 1 Study flow chart.
AB = Antibiotics, RCT = randomised controlled trial, RTI = respiratory tract infection
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erythrasma, one skin sores, and one infected traumatic lesion. Of the UTI RCTs, seven investigated 
non- specific UTI and one cystitis.
Quality of RCTs over time for each of the conditions
Of the 80 ARI trials, a minimal number of trials were at ‘high RoB' across all domains. On the other 
hand, ‘unclear RoB’ was more common across most domains (Figure 3a). The methodological quality 
of ARI studies improved over time. See Supplementary Figure S1 for RoB assessment for individual 
studies ordered according to year of publishing.
Of the 20 SSTI trials, a ‘high RoB’ was detected in only two of the domains but an ‘unclear RoB’ was 
more common across most domains (Figure 3b). See Supplementary Figure S2 for RoB assessment 
for individual studies.
Across the eight UTI trials, a ‘high RoB’ occurred in five of the domains, with ‘unclear RoB’ common 
across most domains (Figure 3c). See Supplementary Figure S3 for RoB assessment for individual 
studies.
Discussion
Summary
In this rigorous scoping review of RCTs comparing antibiotic treatment with no active treatment for 
common infections, a marked difference was found in the number of trials addressing ARIs (n = 80), 
SSTIs (n = 20), and UTIs (n = 8). The quality of the reported studies was mixed for all three groups of 
infections, with many studies having an unclear or high RoB in many domains.
Reasons for the noticeable differences in the number of studies is unclear. ARIs are more common 
than SSTIs and UTIs, and account for more antibiotic use, but even if this is taken into account, the 
number of trials in ARIs relative to the incidence or prevalence of the condition is still much greater 
Figure 2 Number of randomised controlled trials (RCTs) published every decade for acute respiratory infections (ARIs), skin and soft tissue infections 
(SSTIs), and urinary tract infections (UTIs)
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Figure 3 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages 
across all included studies. ARI = acute respiratory infection. SSTI = skin and soft tissue infection. UTI = urinary 
tract infection
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than for SSTIs or UTIs. One might argue that it is misleading to consider this by condition and it may 
make more sense to consider the number of studies by individual diagnosis. One of the reasons why 
these infections are often classified by system is that there is overlap between individual ‘diseases’ 
(for example, rhinitis, sinusitis, rhinosinusitis, common cold, sore throat, pharyngitis, and tonsillitis). 
Nevertheless, the number of studies was looked at by ‘diagnosis’ and still more were found for ARIs 
(19 for sinusitis, 17 for sore throat, and 14 for otitis media) compared with SSTIs (six for skin abscess 
and four for impetigo) or UTIs (seven for non- specific UTI and one for cystitis).
The quality of RCTs has generally improved over time. Therefore, an argument might be made that 
many of the trials of antibiotics for ARI trials were conducted many decades ago when RCT standards 
were lower, without the availability of a reporting guideline for RCTs (for example, the Consolidated 
Standards of Reporting Trials [CONSORT] statement that was published in 2001), and therefore 
needed repeating more recently, whereas this was not the case for most of the SSTI and UTI trials, 
which were high quality trials conducted more recently. However, although most of the ARI trials were 
conducted prior to 2000, there has been a continuing of more ARI trials than SSTI or UTI trials in more 
recent years. Furthermore, the overall quality of the trials is similar for the three groups of infections.
A gradual increase in the number of SSTI trials conducted over time was found, suggesting that 
there has been an increase in interest about the effectiveness of antibiotics for SSTIs. However, 
although there was an increase in the number of UTI trials in 2001–2010 relative to the decades 
before, no trials were found on the effectiveness of antibiotics published since 2010. Another possible 
explanation for the findings could be that despite there being a relatively small number of trials 
conducted for SSTIs and UTIs they were nevertheless able to produce more certain results such that 
further trials were not indicated, whereas for ARIs the effect sizes have been smaller and/or the results 
less conclusive, resulting in the need for further studies. However, this argument is not supported as 
the body of evidence does not provide definitive answers about the effects of antibiotic treatment 
for SSTIs and UTIs. For example, the available evidence suggests that oral antibiotics are inferior to 
topical antibiotics for localised impetigo and there are insufficient data on their effectiveness for non- 
localised impetigo,10 yet they are frequently used for all forms of impetigo. For UTI, there is evidence 
from a meta- analysis that antibiotics increase the chance of cure or improvement compared with 
placebo in women with uncomplicated UTI.11,12 However, there is a reasonably high spontaneous 
cure rate,13 complications are rare, adverse effects are relatively frequent, and there is uncertainty in 
relation to how the effectiveness varies by baseline symptoms and risk factors.
Strengths and limitations
Comprehensive search strategies were used for this scoping review. It had at least two reviewers who 
independently decided on the eligibility of each paper, with a third reviewer as an arbiter. Independent 
assessments were conducted of the RoB for each RCT. The purpose of this review was to identify and 
compare the quantity and quality of research evidence for the three groups of common infections 
rather than establish a pooled estimate of effect. It could be argued that the number of studies is 
not important, and that recommendations should consider the effect sizes and confidence intervals 
found in the available studies, and possibly the overall number of patients included. Nevertheless, as 
discussed above, uncertainty regarding the use of antibiotics remains for many SSTI and UTI scenarios. 
A potential limitation is that only RCTs with placebo or no active treatment as a comparator were 
included. However, for conditions where there are strong clinical beliefs about the effectiveness of 
antibiotics, such as cellulitis and UTI, it may be difficult to conduct trials with no active comparator and 
studies comparing antibiotics with other treatments, such as analgesics, may be appropriate.
Comparison with existing literature
To the authors’ knowledge, no other studies have directly compared the quantity and quality of RCTs 
assessing the effects of antibiotics for ARIs, UTIs, and SSTIs. In a study looking at the extent to which 
recommendations for primary care practice are guided by high quality evidence within the different 
clinical areas,14 Ebell et al found that only 18% of the recommendations for primary care are based 
on evidence from consistent high quality studies and some clinical areas were most investigated 
with the highest grade A (using the Strength of Recommendations Taxonomy [SORT]15) clinical 
recommendations: such as pregnancy and childcare, cardiovascular, and other areas with the least 
type of recommendations such as musculoskeletal, rheumatological, and haematological.
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Implications for research and practice
This scoping review has highlighted a sparsity of trials assessing the effects of antibiotics in people 
with SSTIs and UTIs, relative to the number of trials assessing this question for ARIs. This suggests an 
important gap in the evidence that needs to be addressed by conducting further high quality trials in 
patients with SSTIs and UTIs. Clinicians have to contend with greater uncertainty about the benefits 
and harms of interventions (in this case, antibiotics for SSTIs and UTIs), which are underpinned by 
much less high quality empirical evidence, denoting a weaker recommendation. Communication of 
the ambiguity of evidence is vital to allow patients to make an informed decision regarding their 
treatment option. Resistance to antibiotics that are typically used to treat SSTI, such as flucloxacillin, 
and UTI, such as trimethoprim, is common and problematic; therefore, it is particularly important 
to address antimicrobial stewardship in these areas. The first step in doing so is to generate robust 
evidence regarding the benefits and harms of using antibiotics to treat these conditions.
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